Asan Medical Center
Seoul, 138-736, South Korea
NCT Number: NCT00770523
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients with Hematologic Malignancies.
Looking for future studies?
Notify Me15 year–55 year
All sexes
Observational
Seoul, 138-736, South Korea
Primary end points are treatment-related mortality and engraftment. Secondary end points are regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-Patients should have an unrelated donor who is matched for HLA-A and -B by serology and for -DRB1 by molecular typing.
Exclusion criteria
Time frame: all cause mortality
Time frame: Time point(s) at which outcome measure is assessed.
Cooperative Study Group A for Hematology
Network
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients With Hematologic Malignancies
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04696809
Hematologic Diseases, Hematologic Malignancies
Chiba, Japan
View Trial DetailsNCT02494258
Hematologic Diseases, Hematologic Malignancies
Gainesville, Florida, United States
View Trial DetailsNCT05433090
Hematologic Diseases, Hematologic Malignancies
Rochester, New York, United States
View Trial DetailsNCT06900114
Bacterial Infections and Mycoses, COVID-19
Tianjin, China
View Trial Details